Addition of SGLT2 inhibitor to GLP‐1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control

In conclusion, patients with type 2 diabetes who require further improvement in glycaemic control despite the addition of a GLP‐1 RA to their regimen can be considered for an SGLT2 inhibitor. The mechanism of action may be synergistic and has the advantage of promoting further weight loss. Copyright © 2016 John Wiley & Sons.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fpdi.2018

Source: Practical Diabetes - May 22, 2016 Category: Endocrinology Authors: Louise Curtis, Malik Asif Humayun, James Walker, Kerri Hampton, Helen Partridge Tags: Original article Source Type: research